We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+17.63%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.7B
AUM Growth
+$43.5M
Cap. Flow
-$109M
Cap. Flow %
-6.45%
Top 10 Hldgs %
43.98%
Holding
67
New
4
Increased
4
Reduced
33
Closed
4
Avg Time Held
3.3 years
Top 10 Avg Time Held
1.6 years
Top 20 Avg Time Held
1.4 years

Top Buys

Rank Stock Value
1
ORKA icon
Oruka Therapeutics
ORKA
+$14.3M
2
BNTX icon
BioNTech
BNTX
+$14.2M
3
RGNX icon
Regenxbio
RGNX
+$3.94M
4
ATXS icon
Astria Therapeutics
ATXS
+$3.46M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$3.13M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$40.7M
2
FOLD icon
Amicus Therapeutics
FOLD
+$25.6M
3
BPMC icon
Blueprint Medicines
BPMC
+$10.2M
4
KYMR icon
Kymera Therapeutics
KYMR
+$8.21M
5
TRDA icon
Entrada Therapeutics
TRDA
+$7.99M

Sector Composition

Rank Sector Weight
1 Healthcare 97.73%
2 Industrials 2.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LVTX icon
51
DELISTED
LAVA Therapeutics
LVTX
$3.44M 0.2%
2,074,372
– –
2021 Q1
14 quarters
ATXS icon
52
DELISTED
Astria Therapeutics
ATXS
$3.42M 0.2%
+310,884
New +$3.46M
2024 Q3
0 quarters
IVVD icon
53
Invivyd
IVVD
$197M
$3.13M 0.18%
3,065,714
– –
2021 Q3
12 quarters
XERS icon
54
Xeris Biopharma Holdings
XERS
$1.84B
$2.98M 0.18%
1,046,587
– –
2018 Q2
25 quarters
GRTS icon
55
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.85M 0.17%
4,920,178
-187,554
-4% -$105K
2018 Q3
24 quarters
PEN icon
56
Penumbra
PEN
$12.7B
$2.69M 0.16%
+13,847
New +$2.62M
2024 Q3
0 quarters
CABA icon
57
Cabaletta Bio
CABA
$263M
$2.09M 0.12%
442,826
– –
2019 Q4
19 quarters
ALLK icon
58
DELISTED
Allakos
ALLK
$2.01M 0.12%
3,077,828
– –
2018 Q3
24 quarters
ACHL
59
DELISTED
Achilles Therapeutics
ACHL
$1.64M 0.1%
1,608,089
– –
2021 Q1
14 quarters
KLRS icon
60
Kalaris Therapeutics
KLRS
$52.1M
$1.54M 0.09%
82,955
– –
2020 Q3
16 quarters
RAPT icon
61
DELISTED
RAPT Therapeutics
RAPT
$1.01M 0.06%
63,067
-4,018
-6% -$81.3K
2022 Q1
10 quarters
ADAP
62
DELISTED
Adaptimmune Therapeutics
ADAP
$680K 0.04%
715,607
– –
2023 Q2
5 quarters
HOOK icon
63
DELISTED
HOOKIPA Pharma
HOOK
$457K 0.03%
106,376
-1
-0% -$5
2019 Q2
21 quarters
BPMC icon
64
DELISTED
Blueprint Medicines
BPMC
– –
-94,405
Closed -$10.2M –
LAB icon
65
Standard BioTools
LAB
$258M
– –
-411,631
Closed -$729K –
TKNO icon
66
Alpha Teknova
TKNO
$408M
– –
-154,509
Closed -$212K –
TRDA icon
67
Entrada Therapeutics
TRDA
$186M
– –
-560,971
Closed -$7.99M –
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2024 Portfolio in Review

As of Q3 2024, Redmile Group held 67 positions worth $1.7B, up 2.6% from $1.65B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group withdrew a net $109M in Q3 2024, closing 4 positions and reducing 33 holdings. Its most notable exit was Blueprint Medicines, an estimated $10.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in Oruka Therapeutics worth $10.1M.

  • Redmile Group's largest Q3 2024 buy was Oruka Therapeutics: 411,728 shares worth $10.1M.
  • Redmile Group added most to Regenxbio in Q3 2024, an estimated $3.94M increase.
  • Redmile Group's biggest Q3 2024 reduction was Krystal Biotech, cutting an estimated $40.7M.
  • Redmile Group fully exited Blueprint Medicines in Q3 2024, selling an estimated $10.2M.
  • Redmile Group's ten largest holdings make up 44% of its $1.7B portfolio in Q3 2024.
  • Redmile Group opened 4 new positions and closed 4 in Q3 2024.
  • Redmile Group's portfolio value rose 2.6% quarter-over-quarter to $1.7B.

Based on Redmile Group's 13F filing for Q3 2024, filed 14 Nov 2024.